MD2336F2 - Hidrat cristalin de hidroclorura de 6-hidroxi-3-(4-[2-(piperidina-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obtinere, compozitie farmaceutica care il contine si utilizarea pentru inhibarea starilor patologice si activarea colinacetiltransferazei - Google Patents

Hidrat cristalin de hidroclorura de 6-hidroxi-3-(4-[2-(piperidina-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obtinere, compozitie farmaceutica care il contine si utilizarea pentru inhibarea starilor patologice si activarea colinacetiltransferazei Download PDF

Info

Publication number
MD2336F2
MD2336F2 MDA20000162A MD20000162A MD2336F2 MD 2336 F2 MD2336 F2 MD 2336F2 MD A20000162 A MDA20000162 A MD A20000162A MD 20000162 A MD20000162 A MD 20000162A MD 2336 F2 MD2336 F2 MD 2336F2
Authority
MD
Moldova
Prior art keywords
benzo
methoxyphenyl
piperidine
phenoxy
ethoxy
Prior art date
Application number
MDA20000162A
Other languages
English (en)
Other versions
MD20000162A (ro
MD2336G2 (ro
Inventor
Julie Kay Bush
Preston Charles Conrad
Merlyn Gerard Flom
Wayne Douglas Luke
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MD20000162A publication Critical patent/MD20000162A/ro
Publication of MD2336F2 publication Critical patent/MD2336F2/ro
Publication of MD2336G2 publication Critical patent/MD2336G2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MDA20000162A 1999-07-29 2000-07-28 Hidrat cristalin de hidroclorură de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obţinere , compoziţie farmaceutică care îl conţine şi utilizarea pentru inhibarea stărilor patologice şi activarea colinacetiltransferazei MD2336G2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (3)

Publication Number Publication Date
MD20000162A MD20000162A (ro) 2001-04-30
MD2336F2 true MD2336F2 (ro) 2003-12-31
MD2336G2 MD2336G2 (ro) 2004-06-30

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20000162A MD2336G2 (ro) 1999-07-29 2000-07-28 Hidrat cristalin de hidroclorură de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obţinere , compoziţie farmaceutică care îl conţine şi utilizarea pentru inhibarea stărilor patologice şi activarea colinacetiltransferazei

Country Status (44)

Country Link
EP (1) EP1204656A2 (ro)
JP (1) JP2001064277A (ro)
KR (1) KR100697177B1 (ro)
CN (1) CN1138770C (ro)
AR (1) AR031073A1 (ro)
AT (1) AT502318A1 (ro)
AU (1) AU6335600A (ro)
BE (1) BE1013411A3 (ro)
BR (1) BR0003209A (ro)
CA (1) CA2314682A1 (ro)
CO (1) CO5180570A1 (ro)
CZ (1) CZ299311B6 (ro)
DE (1) DE10036854A1 (ro)
DK (1) DK200001151A (ro)
DZ (1) DZ3060A1 (ro)
FI (1) FI20001722L (ro)
FR (1) FR2796944B1 (ro)
GB (1) GB2352717A (ro)
GR (1) GR1004084B (ro)
HR (1) HRP20000503B1 (ro)
HU (1) HUP0003001A2 (ro)
ID (1) ID27078A (ro)
IL (1) IL137553A (ro)
IT (1) IT1318660B1 (ro)
LT (1) LT4790B (ro)
LU (1) LU90617B1 (ro)
LV (1) LV12623B (ro)
MD (1) MD2336G2 (ro)
MX (1) MXPA00007461A (ro)
MY (1) MY128764A (ro)
NL (1) NL1015821C2 (ro)
NO (1) NO20003879L (ro)
PE (1) PE20010385A1 (ro)
PL (1) PL341749A1 (ro)
PT (1) PT102502A (ro)
RO (1) RO121851B1 (ro)
SE (1) SE0002792L (ro)
SG (1) SG91296A1 (ro)
SI (1) SI20426A (ro)
SV (1) SV2002000132A (ro)
TR (1) TR200002206A2 (ro)
TW (1) TWI276437B (ro)
UA (1) UA72885C2 (ro)
WO (1) WO2001009116A2 (ro)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
CZ20023651A3 (cs) * 2000-05-08 2003-02-12 Eli Lilly And Company Stabilizované přípravky 6-hydroxy-3-(4-[2-(piperidin-1-yl)-ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen a jejich sole
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
US20040014672A1 (en) * 2000-10-20 2004-01-22 Luke Wayne Douglas Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
WO2002042289A2 (en) 2000-11-27 2002-05-30 Eli Lilly And Company Process for preparing 3-aryl-benzo[b]thiophenes
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
ATE480534T1 (de) * 2004-07-22 2010-09-15 Lilly Co Eli Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113013A1 (en) * 1995-02-28 2001-07-04 Eli Lilly & Company Benzothiophene compounds, intermediates, compositions and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Also Published As

Publication number Publication date
LT2000076A (lt) 2001-02-26
RO121851B1 (ro) 2008-06-30
HUP0003001A2 (hu) 2002-04-29
NL1015821A1 (nl) 2001-01-30
GR1004084B (el) 2002-12-11
DZ3060A1 (fr) 2004-05-22
JP2001064277A (ja) 2001-03-13
HK1035370A1 (en) 2001-11-23
SE0002792D0 (sv) 2000-07-28
NO20003879L (no) 2001-01-30
NL1015821C2 (nl) 2002-01-03
TWI276437B (en) 2007-03-21
PT102502A (pt) 2001-01-31
KR20010049916A (ko) 2001-06-15
CZ299311B6 (cs) 2008-06-18
AU6335600A (en) 2001-02-19
HRP20000503B1 (en) 2008-04-30
BR0003209A (pt) 2001-03-20
SE0002792L (sv) 2001-01-30
CN1288007A (zh) 2001-03-21
WO2001009116A3 (en) 2001-05-17
CN1138770C (zh) 2004-02-18
LU90617B1 (fr) 2001-06-15
UA72885C2 (uk) 2005-05-16
GB0018641D0 (en) 2000-09-13
LV12623A (en) 2001-03-20
CA2314682A1 (en) 2001-01-29
CO5180570A1 (es) 2002-07-30
FR2796944A1 (fr) 2001-02-02
ID27078A (id) 2001-02-22
FR2796944B1 (fr) 2003-01-31
AT502318A1 (de) 2007-02-15
SG91296A1 (en) 2002-09-17
PE20010385A1 (es) 2001-04-06
HU0003001D0 (en) 2000-10-28
GR20000100265A (el) 2001-03-30
LT4790B (lt) 2001-05-25
IE20000605A1 (en) 2001-04-04
ITMI20001759A0 (it) 2000-07-28
TR200002206A2 (tr) 2001-03-21
FI20001722A7 (fi) 2001-01-30
HRP20000503A2 (en) 2001-06-30
ITMI20001759A1 (it) 2002-01-28
PL341749A1 (en) 2001-02-12
EP1204656A2 (en) 2002-05-15
FI20001722A0 (fi) 2000-07-28
MD20000162A (ro) 2001-04-30
MD2336G2 (ro) 2004-06-30
CZ20002716A3 (en) 2001-05-16
LV12623B (en) 2001-07-20
NO20003879D0 (no) 2000-07-28
IL137553A0 (en) 2001-07-24
FI20001722L (fi) 2001-01-30
MXPA00007461A (es) 2004-07-16
KR100697177B1 (ko) 2007-03-21
DK200001151A (da) 2001-01-30
DE10036854A1 (de) 2001-03-01
MY128764A (en) 2007-02-28
SV2002000132A (es) 2002-06-07
WO2001009116A2 (en) 2001-02-08
AR031073A1 (es) 2003-09-10
GB2352717A (en) 2001-02-07
SI20426A (sl) 2001-06-30
IT1318660B1 (it) 2003-08-27
IL137553A (en) 2005-09-25
BE1013411A3 (fr) 2001-12-04

Similar Documents

Publication Publication Date Title
MD2336F2 (ro) Hidrat cristalin de hidroclorura de 6-hidroxi-3-(4-[2-(piperidina-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obtinere, compozitie farmaceutica care il contine si utilizarea pentru inhibarea starilor patologice si activarea colinacetiltransferazei
MD2335G2 (ro) Hidrat cristalin de hidroclorură de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofen, procedeu de obţinere, compoziţie farmaceutică care îl conţine şi utilizarea pentru inhibarea stărilor patologice şi activarea colinacetiltransferazei
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
CA2228997A1 (en) Benzothiophene compounds
AU1296902A (en) Isoquinolinone potassium channel inhibitors
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CA2377803A1 (en) Phenyl sulfamate derivatives
AU2002221080A1 (en) Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
WO2002034741A3 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
RU2000120574A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
RU2000120575A (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗ[b]ТИОФЕНА ГИДРОХЛОРИДА
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CA2421302A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees